Zobrazeno 1 - 10
of 807
pro vyhledávání: '"Shaker A, Mousa"'
Autor:
Ali H. El-Far, Kavitha Godugu, Taher A. Salaheldin, Noureldien H. E. Darwish, Amna A. Saddiq, Shaker A. Mousa
Publikováno v:
Biomedicines, Vol 12, Iss 10, p 2305 (2024)
The journal retracts the article, “Nanonutraceuticals: Anti-Cancer Activity and Improved Safety of Chemotherapy by Costunolide and Its Nanoformulation against Colon and Breast Cancer” [...]
Externí odkaz:
https://doaj.org/article/e89360bb2165489fb06432cc16d5664f
Autor:
Kazutoshi Fujioka, Mostafa I. Fekry, Jeanne M. Rumsey, Toni Steiner, David Thompson, Shaker A. Mousa
Publikováno v:
Clinical and Translational Science, Vol 16, Iss 6, Pp 987-1001 (2023)
Abstract The objective of the current study was to identify potential drug–drug interactions (DDIs) with the drug candidate fb‐PMT, a novel anticancer thyrointegrin αvß3 antagonist. This was accomplished by using several in vitro assays to stud
Externí odkaz:
https://doaj.org/article/442f979fd53f48b787fe4e6b8a1cad97
Autor:
Weikun Li, Murat Yalcin, Dhruba J. Bharali, Qishan Lin, Kavitha Godugu, Kazutoshi Fujioka, Kelly A. Keating, Shaker A. Mousa
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-2 (2023)
Externí odkaz:
https://doaj.org/article/319bfe0b95d24207b2592b5b0323bc7d
Publikováno v:
Cancer Cell International, Vol 22, Iss 1, Pp 1-11 (2022)
Abstract Hepatocellular carcinoma (HCC) is the fifth most common malignant cancer and the third most frequent cause of tumour-related mortality worldwide. Currently, several surgical and medical therapeutic strategies are available for HCCs; however,
Externí odkaz:
https://doaj.org/article/f12adc66f2d241a2ae78b2bb0167bb5f
Publikováno v:
Clinical and Translational Science, Vol 15, Iss 2, Pp 353-360 (2022)
Abstract Hyperphosphatemia is present in most patients with end‐stage renal disease (ESRD) and has been associated with increased cardiovascular mortality. Phosphate binders (calcium‐based and calcium free) are the mainstay pharmacologic treatmen
Externí odkaz:
https://doaj.org/article/bd9e71e7e96543269fd8c83ca9570bbc
Publikováno v:
Frontiers in Endocrinology, Vol 14 (2023)
The principal hormonal product of the thyroid gland, L-thyroxine (T4), is a prohormone for 3,3’,5-triiodo-L-thyronine, T3, the major ligand of nuclear thyroid hormone receptors (TRs). At a cell surface thyroid hormone analogue receptor on cancer ce
Externí odkaz:
https://doaj.org/article/6ce095d67c444bdb857b3b589c038141
Publikováno v:
Frontiers in Endocrinology, Vol 13 (2023)
Thyroid hormone as L-thyroxine (T4) acts nongenomically at physiological concentrations at its cancer cell surface receptor on integrin αvβ3 (‘thyrointegrin’) to cause cancer cell proliferation. In the case of estrogen receptor (ERα)-positive
Externí odkaz:
https://doaj.org/article/fa616116676b4194aa1c9e0a4ffda641
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
We have recently reported on the development of fb-PMT (NP751), a conjugate of the thyroid hormone metabolite tetraiodothyroacetic acid (tetrac) and monodisperse polyethylene glycol 36. It exhibited high affinity for thyrointegrin αvβ3 receptor and
Externí odkaz:
https://doaj.org/article/9073dd66eb774f778f855171de6cefd0
Publikováno v:
AAPS Open, Vol 7, Iss 1, Pp 1-9 (2021)
Abstract We previously developed a triazole modified tetraiodothyroacetic acid (TAT) conjugated to a polyethylene glycol (PEG)-based thyrointegrin αvβ3 antagonist targeted compound, called P-bi-TAT. It exhibited potent anti-angiogenic and anticance
Externí odkaz:
https://doaj.org/article/3b33c07f08864402b7001600fbedd8d2
Autor:
Amna A. Saddiq, Ali H. El-Far, Shymaa Abdullah Mohamed Abdullah, Kavitha Godugu, Omar A. Almaghrabi, Shaker A. Mousa
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Cancer can develop due to abnormal cell proliferation in any body’s cells, so there are over a hundred different types of cancer, each with its distinct behavior and response to treatment. Therefore, many studies have been conducted to slow cancer
Externí odkaz:
https://doaj.org/article/b14610cd1a574943a85f1b31dd2f507a